Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu).
Authors
- Zhiguo Luo (ORCID: https://orcid.org/0000-0003-0389-2350)
- Yanjing Guo (ORCID: https://orcid.org/0000-0002-3745-5186)
- Qianming Bai (ORCID: https://orcid.org/0000-0003-0657-9845)
- Juefeng Wan (ORCID: https://orcid.org/0000-0001-5361-1663)
- Xin Liu (ORCID: https://orcid.org/0000-0002-3486-5753)
- Qifeng Wang (ORCID: https://orcid.org/0000-0001-8544-9007)
- Xinhong He (ORCID: https://orcid.org/0000-0002-1291-477X)
- Xiaowei Zhang (ORCID: https://orcid.org/0009-0009-5053-3300)
- Jingjing Wu (ORCID: https://orcid.org/0009-0002-1472-3640)
Institutions
- Fujian Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Jiangyin People's Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.3389/fonc.2025.1537714
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China